by Barry McGuinness | May 22, 2022 | Drug discovery programmes, Immuno-oncology
Duke Street Bio – DDR & IO biotech emerges from stealth mode to discuss its next generation PARP1 and PARP7 inhibitor programmes Since 2019 the management team behind small molecule immuno-oncology biotech IOmet Pharma, acquired by Merck & Co (known as...
Recent Comments